Jon Glass
Expertise in
28
conditions

Dr. Jon Glass

Neurology | Oncology
333 Laurel Oak Road, 
Voorhees, NJ 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
28
conditions
333 Laurel Oak Road, 
Voorhees, NJ 

Overview

Jon Glass is a Neurologist and an Oncologist practicing medicine in Voorhees, New Jersey.

Dr. Glass is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, and Brain Tumor.

Dr. Glass is board certified in Neurology. He is actively involved in clinical research, co-authoring 30 peer reviewed articles and participating in 5 clinical trials. Dr. Glass is currently accepting new patients.

Specialties

Neurology
Oncology

Licenses

Specialist in PA

Board Certifications

Neurology

Fellowships

Massachusetts General Hospital

Hospital Affiliations

Jefferson Stratford Hospital
Jefferson Health- Northeast
Jefferson Abington Hospital
Thomas Jefferson University Hospital
Jefferson Abington Hospital
Jefferson Cherry Hill Hospital
Jefferson Lansdale Hospital
Jefferson Stratford Hospital
Jefferson Washington Township Hospital
Thomas Jefferson University Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

Voorhees Specialty Care
333 Laurel Oak Road, Voorhees, NJ 08043
Other Locations
Vickie & Jack Farber Institute for Neuroscience - 950 Pulaski Drive
950 Pulaski Drive, Suite 120, King Of Prussia, PA 19406

Additional Areas of Focus

Dr. Glass has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Astrocytoma
Brain Tumor
Neurofibromatosis Type 1 (NF1)
Craniopharyngioma
Acoustic Neuroma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Completed
Publish Date: April 22, 2026
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2026
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas
Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 1
Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Glioblastoma Multiforme (GBM).
Standard Chemotherapy Versus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Glioblastoma Multiforme (GBM).
Enrollment Status: Completed
Publish Date: April 15, 2025
Intervention Type: Diagnostic test, Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

30 Total Publications

Case report: durable response of gliomatosis cerebri with concurrent tumor-treating fields (TTFields) and chemoradiotherapy treatment.
Case report: durable response of gliomatosis cerebri with concurrent tumor-treating fields (TTFields) and chemoradiotherapy treatment.
Journal: Chinese clinical oncology
Published: October 02, 2023
Similar Doctors
Expertise in
17
conditions
Dr. Iyad Alnahhas
Neurology | Oncology
Expertise in
17
conditions
Dr. Iyad Alnahhas
Neurology | Oncology
Referral may be required
Before you request

Medical Oncology & Infusion Suite - 900 Medical Center Drive

900 Medical Center Drive, Suite 200, 
Sewell, NJ 
 (8.4 miles away)
856-557-7900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Iyad Alnahhas is a Neurologist and an Oncologist practicing medicine in Sewell, New Jersey. Dr. Alnahhas is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Alnahhas is board certified in Neurology. Dr. Alnahhas is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

University Of Pennsylvania

3400 Civic Center Blvd, 
Philadelphia, PA 
 (13.1 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jakub Svoboda is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Svoboda is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Classical Hodgkin Lymphoma, B-Cell Lymphoma, and Bone Marrow Aspiration.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required
Before you request

Abramson Cancer Center Perelman 2nd Floor West

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
 (13.0 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arati Desai is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Desai is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri. Dr. Desai is board certified in Medical Oncology, 2008, Hospice And Palliative Medicine, 2012, and Internal Medicine, 2004. Dr. Desai is currently accepting new patients.

Frequently Asked Questions about Dr. Jon Glass

How do I make an appointment with Dr. Jon Glass?

You can book an appointment with Dr. Jon Glass by calling their office at 215-955-1234. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jon Glass a top-rated expert for Glioma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jon Glass is classified as an Elite expert for Glioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jon Glass specialize in?

While Dr. Jon Glass is a Neurology, they have specific expertise in Glioma, Astrocytoma, and Glioblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Jon Glass participate in research or clinical trials?

Yes. Dr. Jon Glass has published 30 articles and abstracts on conditions like Glioma. You can view a list of Dr. Jon Glass's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jon Glass accept my insurance?

Dr. Jon Glass accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 215-955-1234 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Glass's expertise for a condition
ConditionClose
View All 17 Distinguished Conditions
View All 10 Advanced Conditions
View All 46 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile